Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of LncRNA XLOC_057528 inhibitor to preparation of medicines for promoting blood vessel regeneration

An angiogenesis and inhibitor technology, applied in the field of cell engineering and genetic engineering, to achieve the effect of reducing the number of tubes

Active Publication Date: 2019-11-22
GUANGDONG LAB ANIMALS MONITORING INST +1
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, many literatures have reported that lncRNA affects angiogenesis by regulating human umbilical vein endothelial cells (HUVECs) in tumor diseases, but angiogenesis after MI is rarely reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of LncRNA XLOC_057528 inhibitor to preparation of medicines for promoting blood vessel regeneration
  • Application of LncRNA XLOC_057528 inhibitor to preparation of medicines for promoting blood vessel regeneration
  • Application of LncRNA XLOC_057528 inhibitor to preparation of medicines for promoting blood vessel regeneration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] 1. Construction of gene overexpression vector

[0031] The lncRNA XLOC_057528 related to myocardial infarction was screened from the differential lncRNA as the research object. DNAMAN software analysis found that the full-length sequence of the lncRNA XLOC_057528 gene has no Kpn I and Nhe I restriction endonuclease sites, but the pcDNA3.1(-) vector (purchased from BioMed, Cat. No. CL408-01) has Kpn I and NheI restriction sites. The primer premier 5.0 software designed the full-length primers of the gene, and the Kpn I and Nhe I restriction site sequences were added to the upstream and downstream primers respectively. Using human umbilical vein endothelial cell cDNA as a template, PCR amplifies the target fragment (the amplified target fragment is the lncRNAXLOC_057528 sequence, and its nucleotide sequence is shown in SEQ ID NO.1), purified and recovered, double enzyme digested, and connected to pcDNA3 .1 (-) carrier, transformation, screening, and sequencing identific...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Login to View More

Abstract

The invention discloses an application of an LncRNA XLOC_057528 inhibitor to preparation of medicines for promoting blood vessel regeneration. Overexpression and silence of lncRNA XLOC_057528 confirmthat lncRNA XLOC_057528 can influence expression of a p53 gene and protein to human umbilical vein endothelial cells, and besides, confirm that the lncRNA XLOC_057528 participates in promotion of proliferation of the human umbilical vein endothelial cells, restraining of apoptosis of the human umbilical vein endothelial cells, and restraining of canaliculization of the human umbilical vein endothelial cells, and further confirm that the lncRNA XLOC_057528 can participate in restraining of blood vessel regeneration after miocardial infarction. Therefore, the lncRNA XLOC_057528 inhibitor can beused for preparing the medicines for promoting blood vessel regeneration, and particularly the lncRNA XLOC_057528 inhibitor can be used for preparing the medicines for promoting blood vessel regeneration after miocardial infarction.

Description

technical field [0001] The invention belongs to the technical field of cell engineering and genetic engineering, and specifically relates to the application of an inhibitor of long-chain non-coding RNA XLOC_057528 (lncRNA XLOC_057528) in the preparation of drugs for promoting angiogenesis. Background technique [0002] Myocardial infarction (MI) is a cardiovascular disease that seriously endangers human health. The disease is based on coronary atherosclerotic stenosis, and the blood clot formed blocks the coronary lumen. Due to long-term ischemia, it eventually leads to myocardial necrosis. Known as "the number one killer of human health". [0003] Angiogenesis refers to the development of new blood vessels from existing capillaries or post-capillary veins, mainly through budding to form fully functional blood vessels, mainly including proliferation, budding and migration of endothelial cells. In the damaged heart, effective vascular remodeling can restore the lesion area t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6883A61K45/00A61K31/7105A61K48/00A61P9/00A61P9/10
CPCC12Q1/6883A61K45/00A61K31/7105A61P9/00A61P9/10C12Q2600/106C12Q2600/178
Inventor 王希龙张豪潘金春袁晓龙龚宝勇唐龙龙高洪彬李加琪谭伟江张哲梁十
Owner GUANGDONG LAB ANIMALS MONITORING INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com